BookBengt Källén.
Summary: This book is the combination of the literature on maternal drug use and birth defects with a set of new data on most types of drugs. In this book, for each group of drugs the relevant scientific literature on drug teratogenicity is presented, with consideration of possible sources of error and also what the findings may mean from a practical point of view. The book also adds data from the Swedish health registers for 1996-2013 based on more than 1.7 million early-pregnancy midwife interviews. Maternal Drug Use and Infant Congenital Malformations will find an engaged audience among people working within the field, and will be of interest to healthcare providers, especially obstetricians and other clinicians who treat women of childbearing age. -- Provided by publisher.
Contents:
Intro; Preface; Contents; Abbreviations;
Chapter 1: Background; Introduction; Ascertainment of Congenital Malformations; Other Outcomes; Ascertainment of Maternal Drug Use; Case-Control Methods; Prospective Methods Based on Interviews or Questionnaires; Teratology Information Services (TIS); Pregnancy Registers; Medical Documents and Prescription Registers; The Swedish Health Registers; Confounding; Mass Significance; References;
Chapter 2: Maternal Use of Antacids or Drugs for Gastroesophageal Reflux Diagnosis (GERD) or Stomach Ulcer and Infant Congenital Malformations; Introduction Data from the Swedish Health RegistersMalformation Risk After Maternal Use of Antacids; Malformation Risk After Maternal Use of Drugs for GERD; Discussion; References;
Chapter 3: Maternal Use of Drugs for Intestinal Problems, Except Intestinal Inflammations, and Infant Congenital Malformations; Introduction; Data from the Swedish Health Registers; Malformation Risk After the Use of Drugs for Functional Intestinal Disorders; Malformation Risk After the Use of Laxatives; Malformation Risk After the Use of Drugs for Intestinal Infections; Malformation Risk After the Use of Drugs for Diarrhea Malformation Risk After the Use of Anti-Propulsive Drugs (Loperamide)Discussion; References;
Chapter 4: Maternal Use of Drugs for Inflammatory Intestinal Disease and Infant Congenital Malformations; Introduction; Data from the Swedish Health Registers; Congenital Malformations After Maternal Use of Drugs for Intestinal Inflammatory Disease; Discussion; References;
Chapter 5: Maternal Use of Anti-Obesity Drugs and Infant Congenital Malformations; Introduction; Data from the Swedish Health Registers; Discussion; References
Chapter 6: Maternal Use of Insulin or Oral Hypoglycemic Drugs and Infant Congenital MalformationsIntroduction; Data from the Swedish Health Registers; Insulin; Oral Hypoglycemic Agents; Discussion; References;
Chapter 7: Maternal Use of Vitamins and Infant Congenital Malformation; Introduction; Data form the Swedish Health Registers; Malformation Risk After Maternal Use of Multivitamins; Malformation Risk After Maternal Use of Folic Acid; Malformation Risk After Maternal Use of Vitamin B12; Malformation Risk After Maternal Use of Some Other Vitamins; Discussion; References
Chapter 8: Maternal Use of Anticoagulants or Hemostatic Drugs and Infant Congenital MalformationsIntroduction; Data from the Swedish Health Registers; Malformation Risk After Maternal Use of Anticoagulants; Malformation Risk After Maternal Use of Hemostatics; Discussion; References;
Chapter 9: Maternal Use of Drugs for Cardiovascular Diseases and Infant Congenital Malformations; Introduction; Anti-hypertensives; Statins; Data from the Swedish Health Registers; Cardiac Therapy; Drugs Used at Hypertension; Other Anti-hypertensive Drugs; Diuretics; Beta-Blocking Agents; Calcium Channel Blockers